Houston TX 三阴性乳腺癌临床试验
42项针对 三阴性乳腺癌的研究正在 Houston及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
招募中1 期
- University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
招募中1 期
- University of Texas MD Anderson Cancer Center, Houston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
招募中1/2 期
- MD Anderson Cancer Center, Houston
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
招募中1/2 期
- MD Anderson Cancer Center, Houston
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
招募中
- M D Anderson Cancer Center, Houston
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
招募中3 期
- Kelsey-Seybold Clinic - North Houston Campus ( Site 0096), Houston
- Kelsey-Seybold Clinic ( Site 0040), Houston
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
招募中3 期
- Oncology Consultants P.A. ( Site 0107), Houston
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
招募中3 期
- Kelsey-Seybold Clinic ( Site 0042), Houston
- Kelsey-Seybold Clinic ( Site 0088), Houston
- Oncology Consultants P.A. ( Site 0073), Houston
Intratumoral N17350 in Advanced Solid Tumors
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
招募中1 期
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
招募中2 期
- Baylor College of Medicine, Houston
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
招募中1 期
- MD Anderson Cancer Center, Houston
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
招募中3 期
- MD Anderson Cancer Center, Houston
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
招募中1 期
- The University of Texas - MD Anderson Cancer Center, Houston
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
招募中观察性研究
- UT Health Houston, Houston
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
招募中1 期
- MD Anderson Cancer Center, Houston
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
招募中1/2 期
- Research Site, Houston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
招募中1 期
- Normunity Investigational Site, Houston
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
招募中1/2 期
- Houston Methodist Hospital, Houston
SMP-3124LP in Adults With Advanced Solid Tumors
招募中1/2 期
- MD Anderson Cancer Center, Houston
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
招募中1 期
- UT MD Anderson Cancer Center, Houston
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
招募中2/3 期
- (USOR) Texas Oncology, Houston
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
招募中1 期
- Uni Of TX MD Anderson Cancer Cntr, Houston
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
招募中1 期
- The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services, Houston
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
招募中1 期
- The University of Texas - M.D. Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
招募中1/2 期
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
招募中1/2 期
- MD Anderson, Houston
A Study of LY4175408 in Participants With Advanced Cancer
招募中1 期
- MD Anderson Cancer Center, Houston
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
招募中1 期
- The University of Texas MD Anderson Cancer Center /ID# 270059, Houston
Study of XB010 in Subjects With Solid Tumors
招募中1 期
- University of Texas MD Anderson Cancer Center, Houston
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
招募中1 期
- MD Anderson, Houston
- NEXT Texas LLC - Houston, Houston
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
招募中2 期
- Houston Methodist Neal Cancer Center, Houston
- The University of Texas MD Anderson Cancer Center, Houston
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
招募中2 期
- MD Anderson Cancer Center, Houston
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
招募中1 期
- MD Anderson Cancer Center, Houston
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
招募中1/2 期
- M.D. Anderson Cancer Center, Houston
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
招募中1 期
- MD Anderson Cancer Center, Houston
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
招募中2 期
- Harris Health System - Smith Clinic, Houston
- O'Quinn Medical Tower - McNair Campus - Dan L Duncan Comprehensive Cancer Center, Houston
CtDNA Based MRD Testing for NAC Monitoring in TNBC
招募中观察性研究
- The University of Texas MD Anderson Cancer Center, Houston
其他城市的 三阴性乳腺癌试验
- New York City, NY31 项研究
- Nashville, TN28 项研究
- Los Angeles, CA27 项研究
- Boston, MA26 项研究
- San Antonio, TX23 项研究
- St. Louis, MO21 项研究
- Arlington, VA20 项研究
- Atlanta, GA20 项研究
- Dallas, TX18 项研究
- Chicago, IL16 项研究
- Columbus, OH16 项研究
- Grand Rapids, MI15 项研究
Houston的其他研究
- 非小细胞肺癌145 项研究
- 乳腺癌126 项研究
- 癌症（所有类型）121 项研究
- 转移性癌症104 项研究
- 结直肠癌102 项研究
- 卵巢癌89 项研究
- 急性髓系白血病85 项研究
- 肺癌78 项研究
- 前列腺癌76 项研究
- 子宫内膜癌68 项研究
- 胰腺癌61 项研究
- 黑色素瘤59 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。